Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115387 · ClinicalTrials.gov registry record
GARM II: A Study on the Genetics of Age-related Maculopathy
A clinical trial of Age-related Macular Degeneration and Age-related Maculopathy, sponsored by University of California, Los Angeles.
- Active
- Registry status
- 603
- Enrollment target
- 2
- Study locations
NCT01115387: Active study of Age-related Macular Degeneration and Age-related Maculopathy, sponsored by University of California, Los Angeles.
NCT01115387 is a study of Age-related Macular Degeneration and Age-related Maculopathy that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 603 participants, below the 1,500-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (60% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01115387, a study of Age-related Macular Degeneration and Age-related Maculopathy, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- 603 participants
- Enrollment target
- 2
- Study locations
Study Summary
The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65 years old). The purpose of this study is to identify the hereditary and exposure risk factors that lead to the development of ARM (Age related maculopathy). Participants will communicate with the research staff through a protected and confidential website and use this website to complete a number of questionnaires during the course of the study (see below). For genetic analyses, the participants will mail in easily self-collected saliva samples in special containers. Eye photographs and eye health records are sent to the research center from local sources through the Internet. Individuals are not expected to come to UCLA in order to participate. https://jseiclinres.jsei.ucla.edu/garm/ Participants will be expected to answer questionnaires or surveys about medical history, ocular history and visual symptoms, family history, smoking, dietary supplements and light exposure.
Primary Outcome
The primary outcome measure is the presence or absence of early retinal changes with age-related maculopathy in order to develop and test a model which combines genetic, environmental and dietary risk factors to predict which at risk individuals are most likely to develop signs of age-related maculopathy within the study period.
Conditions Studied
Interventions
- OTHER Observational-1
- OTHER Observational-2
Study Locations (2)
California
- Jules Stein Eye Institute, Dept. of Ophthalmology David Geffen School of Medicine at UCLA - Los Angeles
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2011-10-06 |
| Est. Completion | 2027-03 |
What the registry record for NCT01115387 still lists
NCT01115387 is an observational study that tracks outcomes without assigning an intervention. The registered 603 participants enrollment target is mid-sized for trials with a published cap, below the 1,500-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Observational-1 is the first listed.
NCT01115387 reports a single indexed study location in California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01115387 about?
NCT01115387 is a clinical study titled "GARM II: A Study on the Genetics of Age-related Maculopathy". The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65 years old). The purpose of this study is to identify t...
What is the current status of trial NCT01115387?
This trial is currently active not recruiting. The enrollment target is 603 participants. The study started on 2011-10-06. Estimated completion is 2027-03.
What conditions does trial NCT01115387 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Age-related Maculopathy.
What interventions are being tested in trial NCT01115387?
The interventions under investigation include: Observational-1 (OTHER), Observational-2 (OTHER).
Who is sponsoring clinical trial NCT01115387?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01115387 being conducted?
This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01115387's enrollment target sits among peer trials
603 8th of 74 higher than 67 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI